Titre : Agents séquestrants

Agents séquestrants : Questions médicales fréquentes

Termes MeSH sélectionnés :

Cancer-Associated Fibroblasts
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Agents séquestrants : Questions médicales les plus fréquentes", "headline": "Agents séquestrants : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Agents séquestrants : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-03", "dateModified": "2025-04-28", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Agents séquestrants" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Utilisations spécialisées de produits chimiques", "url": "https://questionsmedicales.fr/mesh/D020313", "about": { "@type": "MedicalCondition", "name": "Utilisations spécialisées de produits chimiques", "code": { "@type": "MedicalCode", "code": "D020313", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.720" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Chélateurs", "alternateName": "Chelating Agents", "url": "https://questionsmedicales.fr/mesh/D002614", "about": { "@type": "MedicalCondition", "name": "Chélateurs", "code": { "@type": "MedicalCode", "code": "D002614", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.720.832.500" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Agents chélateurs du calcium", "alternateName": "Calcium Chelating Agents", "url": "https://questionsmedicales.fr/mesh/D065096", "about": { "@type": "MedicalCondition", "name": "Agents chélateurs du calcium", "code": { "@type": "MedicalCode", "code": "D065096", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.720.832.500.204" } } }, { "@type": "MedicalWebPage", "name": "Agents chélateurs du fer", "alternateName": "Iron Chelating Agents", "url": "https://questionsmedicales.fr/mesh/D007502", "about": { "@type": "MedicalCondition", "name": "Agents chélateurs du fer", "code": { "@type": "MedicalCode", "code": "D007502", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.720.832.500.410" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Sidérophores", "alternateName": "Siderophores", "url": "https://questionsmedicales.fr/mesh/D017262", "about": { "@type": "MedicalCondition", "name": "Sidérophores", "code": { "@type": "MedicalCode", "code": "D017262", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.720.832.500.410.750" } } } ] }, { "@type": "MedicalWebPage", "name": "Sidérophores", "alternateName": "Siderophores", "url": "https://questionsmedicales.fr/mesh/D017262", "about": { "@type": "MedicalCondition", "name": "Sidérophores", "code": { "@type": "MedicalCode", "code": "D017262", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.720.832.500.410.750" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Agents séquestrants", "alternateName": "Sequestering Agents", "code": { "@type": "MedicalCode", "code": "D064449", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Xueli Cao", "url": "https://questionsmedicales.fr/author/Xueli%20Cao", "affiliation": { "@type": "Organization", "name": "Beijing Advanced Innovation Center for Soft Matter Science and Engineering, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China." } }, { "@type": "Person", "name": "Yu Xiao", "url": "https://questionsmedicales.fr/author/Yu%20Xiao", "affiliation": { "@type": "Organization", "name": "Ministry of Education Key Laboratory of Protein Science, Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, School of Life Sciences, Tsinghua University, Tsinghua-Peking Center for Life Sciences, Beijing 100084, China." } }, { "@type": "Person", "name": "Erin Huiting", "url": "https://questionsmedicales.fr/author/Erin%20Huiting", "affiliation": { "@type": "Organization", "name": "Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA." } }, { "@type": "Person", "name": "Dong Li", "url": "https://questionsmedicales.fr/author/Dong%20Li", "affiliation": { "@type": "Organization", "name": "Beijing Advanced Innovation Center for Soft Matter Science and Engineering, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China." } }, { "@type": "Person", "name": "Jie Ren", "url": "https://questionsmedicales.fr/author/Jie%20Ren", "affiliation": { "@type": "Organization", "name": "State Key Laboratory for Biology of Plant Diseases and Insect Pests, Ministry of Agriculture, Institute of Plant Protection, Chinese Academy of Agricultural Sciences, Beijing 100081, China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities.", "datePublished": "2023-03-06", "url": "https://questionsmedicales.fr/article/36890105", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.euo.2023.02.011" } }, { "@type": "ScholarlyArticle", "name": "Potential mechanisms of cancer-associated fibroblasts in therapeutic resistance.", "datePublished": "2023-09-04", "url": "https://questionsmedicales.fr/article/37660643", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.biopha.2023.115425" } }, { "@type": "ScholarlyArticle", "name": "Cancer-associated fibroblasts: tumor defenders in radiation therapy.", "datePublished": "2023-08-22", "url": "https://questionsmedicales.fr/article/37607935", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41419-023-06060-z" } }, { "@type": "ScholarlyArticle", "name": "Stromal circuits involving tumor-associated macrophages and cancer-associated fibroblasts.", "datePublished": "2023-06-05", "url": "https://questionsmedicales.fr/article/37342322", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2023.1194642" } }, { "@type": "ScholarlyArticle", "name": "Cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter.", "datePublished": "2024-03-15", "url": "https://questionsmedicales.fr/article/38491511", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12967-024-05085-y" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Actions chimiques et utilisations", "item": "https://questionsmedicales.fr/mesh/D020164" }, { "@type": "ListItem", "position": 3, "name": "Utilisations spécialisées de produits chimiques", "item": "https://questionsmedicales.fr/mesh/D020313" }, { "@type": "ListItem", "position": 4, "name": "Agents séquestrants", "item": "https://questionsmedicales.fr/mesh/D064449" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Agents séquestrants - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Agents séquestrants", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-03", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Agents séquestrants", "description": "Comment diagnostiquer une intoxication aux métaux lourds ?\nQuels examens pour évaluer l'efficacité d'un agent séquestrant ?\nQuels symptômes indiquent un besoin d'agents séquestrants ?\nComment identifier une carence nutritionnelle ?\nQuels signes d'overdose d'agents séquestrants ?", "url": "https://questionsmedicales.fr/mesh/D064449?mesh_terms=Cancer-Associated+Fibroblasts&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Agents séquestrants", "description": "Quels symptômes d'une carence en fer ?\nComment reconnaître une toxicité au plomb ?\nQuels signes d'une carence en calcium ?\nQuels symptômes d'une intoxication au mercure ?\nComment se manifeste une carence en potassium ?", "url": "https://questionsmedicales.fr/mesh/D064449?mesh_terms=Cancer-Associated+Fibroblasts&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Agents séquestrants", "description": "Comment prévenir les carences nutritionnelles ?\nQuelles mesures pour éviter l'exposition aux métaux lourds ?\nComment réduire le cholestérol par l'alimentation ?\nQuels aliments riches en calcium pour la prévention ?\nComment éviter les effets secondaires des séquestrants ?", "url": "https://questionsmedicales.fr/mesh/D064449?mesh_terms=Cancer-Associated+Fibroblasts&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Agents séquestrants", "description": "Quels agents séquestrants pour le cholestérol ?\nComment fonctionnent les agents séquestrants ?\nQuels sont les effets secondaires des agents séquestrants ?\nComment administrer un agent séquestrant ?\nQuels agents séquestrants pour les métaux lourds ?", "url": "https://questionsmedicales.fr/mesh/D064449?mesh_terms=Cancer-Associated+Fibroblasts&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Agents séquestrants", "description": "Quelles complications d'une surconsommation d'agents séquestrants ?\nQuels risques d'une utilisation prolongée ?\nComment les agents séquestrants affectent-ils l'absorption des médicaments ?\nQuelles complications liées à l'intoxication au plomb ?\nQuels effets à long terme des agents séquestrants ?", "url": "https://questionsmedicales.fr/mesh/D064449?mesh_terms=Cancer-Associated+Fibroblasts&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Agents séquestrants", "description": "Quels facteurs augmentent le risque de carences ?\nQui est à risque d'intoxication au mercure ?\nQuels groupes sont vulnérables aux carences en calcium ?\nQuels comportements augmentent le risque d'intoxication aux métaux ?\nQuels facteurs influencent l'absorption des nutriments ?", "url": "https://questionsmedicales.fr/mesh/D064449?mesh_terms=Cancer-Associated+Fibroblasts&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une intoxication aux métaux lourds ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et urinaires peuvent détecter la présence de métaux lourds." } }, { "@type": "Question", "name": "Quels examens pour évaluer l'efficacité d'un agent séquestrant ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des analyses biochimiques peuvent mesurer les niveaux de nutriments ou toxines." } }, { "@type": "Question", "name": "Quels symptômes indiquent un besoin d'agents séquestrants ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme des douleurs abdominales ou des troubles digestifs peuvent indiquer un besoin." } }, { "@type": "Question", "name": "Comment identifier une carence nutritionnelle ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins peuvent révéler des carences en vitamines ou minéraux." } }, { "@type": "Question", "name": "Quels signes d'overdose d'agents séquestrants ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des nausées, vomissements ou diarrhées peuvent signaler une overdose." } }, { "@type": "Question", "name": "Quels symptômes d'une carence en fer ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Fatigue, pâleur, essoufflement et vertiges sont des symptômes courants." } }, { "@type": "Question", "name": "Comment reconnaître une toxicité au plomb ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Des douleurs abdominales, des troubles neurologiques et des anémies peuvent survenir." } }, { "@type": "Question", "name": "Quels signes d'une carence en calcium ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des crampes musculaires, des engourdissements et des troubles de l'humeur peuvent apparaître." } }, { "@type": "Question", "name": "Quels symptômes d'une intoxication au mercure ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des tremblements, des troubles de la mémoire et des problèmes de vision peuvent se manifester." } }, { "@type": "Question", "name": "Comment se manifeste une carence en potassium ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des faiblesses musculaires, des palpitations et des troubles du rythme cardiaque peuvent survenir." } }, { "@type": "Question", "name": "Comment prévenir les carences nutritionnelles ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et variée est essentielle pour éviter les carences." } }, { "@type": "Question", "name": "Quelles mesures pour éviter l'exposition aux métaux lourds ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les aliments contaminés et utiliser des filtres à eau peut réduire l'exposition." } }, { "@type": "Question", "name": "Comment réduire le cholestérol par l'alimentation ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Consommer des fibres solubles et limiter les graisses saturées aide à réduire le cholestérol." } }, { "@type": "Question", "name": "Quels aliments riches en calcium pour la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Les produits laitiers, les légumes verts et les noix sont de bonnes sources de calcium." } }, { "@type": "Question", "name": "Comment éviter les effets secondaires des séquestrants ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Prendre les agents séquestrants avec suffisamment d'eau et suivre les recommandations médicales." } }, { "@type": "Question", "name": "Quels agents séquestrants pour le cholestérol ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les résines comme le cholestyramine sont utilisées pour réduire le cholestérol sanguin." } }, { "@type": "Question", "name": "Comment fonctionnent les agents séquestrants ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Ils se lient aux substances dans l'intestin, empêchant leur absorption dans le sang." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des agents séquestrants ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des effets comme des ballonnements, des nausées et des troubles digestifs peuvent survenir." } }, { "@type": "Question", "name": "Comment administrer un agent séquestrant ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Ils sont généralement pris par voie orale, souvent mélangés à des liquides." } }, { "@type": "Question", "name": "Quels agents séquestrants pour les métaux lourds ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des agents comme l'EDTA sont utilisés pour traiter les intoxications aux métaux lourds." } }, { "@type": "Question", "name": "Quelles complications d'une surconsommation d'agents séquestrants ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Une surconsommation peut entraîner des carences nutritionnelles et des troubles digestifs." } }, { "@type": "Question", "name": "Quels risques d'une utilisation prolongée ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Une utilisation prolongée peut causer des déséquilibres électrolytiques et des carences." } }, { "@type": "Question", "name": "Comment les agents séquestrants affectent-ils l'absorption des médicaments ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent réduire l'absorption de certains médicaments, diminuant leur efficacité." } }, { "@type": "Question", "name": "Quelles complications liées à l'intoxication au plomb ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des complications neurologiques, rénales et cardiovasculaires peuvent survenir." } }, { "@type": "Question", "name": "Quels effets à long terme des agents séquestrants ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des effets à long terme peuvent inclure des carences nutritionnelles et des troubles métaboliques." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de carences ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation déséquilibrée, des maladies chroniques et des régimes restrictifs augmentent le risque." } }, { "@type": "Question", "name": "Qui est à risque d'intoxication au mercure ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes consommant régulièrement des poissons contaminés sont à risque élevé." } }, { "@type": "Question", "name": "Quels groupes sont vulnérables aux carences en calcium ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes âgées, les femmes enceintes et les végétariens peuvent être plus vulnérables." } }, { "@type": "Question", "name": "Quels comportements augmentent le risque d'intoxication aux métaux ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Travailler dans des environnements contaminés ou utiliser des produits non réglementés augmente le risque." } }, { "@type": "Question", "name": "Quels facteurs influencent l'absorption des nutriments ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "L'âge, la santé digestive et les interactions médicamenteuses influencent l'absorption." } } ] } ] }

Sources (10000 au total)

Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities.

Bladder cancer (BLCA) is a highly prevalent tumour and a health problem worldwide, especially among men. Recent work has highlighted the relevance of the tumour microenvironment (TME) in cancer biolog... To review the role of CAFs in BLCA biology and provide an understanding of CAF origin, subtypes, markers, and phenotypic and functional characteristics to improve patient management.... A PubMed search was performed to review manuscripts published using the terms "cancer associated fibroblast" and "bladder cancer" or "urothelial cancer". All abstracts were reviewed, and the full cont... CAFs have been studied less extensively in BLCA than in other tumours. Thanks to new techniques, such as single-cell RNA-seq and spatial transcriptomics, it is now possible to accurately map and molec... Current knowledge of BLCA CAFs and the TME is being increasingly applied to improve BLCA therapy. There is a need to acquire a deeper understanding of CAF biology in BLCA.... Tumour cells are surrounded by nontumoural cells that contribute to the determination of the behaviour of cancers. Among them are cancer-associated fibroblasts. The "neighbourhoods" established throug...

Cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter.

Ovarian cancer (OC) is distinguished by its aggressive nature and the limited efficacy of current treatment strategies. Recent studies have emphasized the significant role of cancer-associated fibrobl... Employing sophisticated machine learning techniques on bulk transcriptomic datasets, we identified fibroblast growth factor 7 (FGF7), derived from CAFs, as a potential oncogenic factor. We investigate... Our findings indicate that higher FGF7 levels correlate with advanced tumor stages, increased vascular invasion, and poorer prognosis. CAFs-derived FGF7 significantly enhanced OC cell proliferation, m... Neutralizing FGF7 in the medium or inhibiting HIF-1α signaling reversed the effects of FGF7-mediated EMT, emphasizing the dependence of FGF7-mediated EMT on HIF-1α activation. These findings suggest t...

Cancer-associated fibroblast-dependent and -independent invasion of gastric cancer cells.

Cancer cells are known to exhibit a cancer-associated fibroblast (CAF)-dependent invasive mode in the presence of CAFs. The purpose of this study was to investigate whether intrinsic factors of gastri... We observed dynamic movement of CAFs, and cancer cells, by time-lapse imaging of 2-D and 3-D collagen invasion models, and evaluated invasion modes of gastric cancer cell lines (MKN-7, MKN-45, and HSC... When MKN-7 and MKN-45 cells were co-cultured with CAFs, CAFs first invade collagen matrix followed by cancer cells (CAF-dependent invasion), whereas HSC44PE cells invaded collagen matrix independent o... These results indicate that in presence of CAFs, gastric cancer cells exhibit both CAF-dependent and -independent modes of invasion, the determinants of which may depend on the intrinsic properties of...